Jinyu Bio-Technology (600201.SH) plans to subscribe to 50 million yuan for the Morning Sun Haoran Core No.2 Private Equity Securities Investment Fund.

Biological shares (600201.SH) announced that in order to improve the efficiency of the company's capital utilization and increase company income, without affecting normal production and operation and effectively controlling risks, the company's wholly-owned subsidiary Jinyu Baoling Biological Pharmaceuticals Co., Ltd. (hereinafter referred to as "Jinyu Baoling") has signed a "Morning Sunshine Hao Ran Core 2 Private Equity Fund Private Equity Fund Contract" with Morning Sunshine (Shenzhen) Private Equity Fund Management Co., Ltd. (hereinafter referred to as "Morning Sunshine Investment") and Guotai Haitong Securities Co., Ltd. (hereinafter referred to as "Guotai Haitong"). The company plans to use its own funds of 50 million yuan to subscribe to the Morning Sunshine Hao Ran Core 2 Private Equity Fund.